Atopic Dermatitis

David Rosmarin, MD, discusses results from ADORING 3 presented at AAD 2025.

New 3-year data from ADjoin demonstrate the efficacy and safety profile of lebrikizumab in moderate to severe atopic dermatitis.

Eapen discussed her research into analyzing the cord blood methylome for markers that predict atopic dermatitis risk at the AAAAI/WAO Joint Congress.

Greiwe discussed findings from the phase 3 ADORING 1 and 2 trials in people as young as 2 years of age.

In these survey findings, a variety of notable findings regarding perceptions of awareness of CHE as well as views on available drugs are highlighted.

A preview of 5 phase 3 clinical trials being presented during the AAD 2025 annual meeting's late-breaking sessions.

Panelists discuss how the emergence of targeted biologics has revolutionized atopic dermatitis treatment by offering effective alternatives to traditional therapies. These agents, including IL-4/IL-13 inhibitors like dupilumab and others targeting specific inflammatory pathways, have provided new options for moderate to severe cases resistant to conventional treatments.

Panelists discuss the current treatment landscape for atopic dermatitis, noting significant advances in biologics and systemic therapies, and share optimism about the future of management, highlighting ongoing research and the potential for more targeted, personalized treatments to improve patient outcomes.

Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.

Our top 5 headlines include an FDA approval, a pair of submissions, data from AAAAI 2025, and more!

Alexis discussed the latest research in the field and new management strategies for children with atopic dermatitis.

These phase 3 data on delgocitinib cream (Anzupgo) 20 mg/g highlight the drug’s potential for adolescents aged 12 years and older with chronic hand eczema (CHE).

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

Kernizan discusses winning the 2024 Society for Pediatric Dermatology Medical Student Mentorship Award and getting into pediatric dermatology as a student.

On Feb. 26, 2025, Arcutis Biotherapeutics announced the FDA's acceptance of their sNDA for roflumilast cream 0.05% in AD for children aged 2 to 5 years.

These data point to increasing omega-3 consumption as a potential preventive strategy against atopic dermatitis.

Ahead of AAAAI 2025, HCPLive spoke with Jaroenpuntaruk about varying hypersensitivity reactions in patients with atopic diseases on biologics.

These findings highlight the prevalence of atopic dermatitis among adults in France, as well as the different factors associated with various disease profiles.

Panelists discuss how primary care physicians often serve as the first point of contact for patients with atopic dermatitis symptoms. Dermatologist referral is typically considered when patients show severe or persistent symptoms despite initial treatment, have unclear diagnosis, require specialized therapies, or experience significant impact on quality of life.

Panelists discuss offering guidance to parents and caregivers experiencing atopic dermatitis for the first time, emphasizing the importance of education on managing flare-ups, proper skin care routines, and setting realistic treatment expectations while also seeking support from health care professionals to navigate the challenges of the condition.

Panelists discuss when to consider adding or switching agents for atopic dermatitis, highlighting alternative treatments for pediatric patients such as biologics and Janus kinase (JAK) inhibitors, and emphasize the importance of tailoring treatment decisions based on efficacy and patient response, citing studies such as Blauvelt 2023, Keow & Abu-Hilal 2024, and JADE EXTEND. They also explore emerging systemic agents such as nemolizumab (IL-31 receptor antagonist) and rocatinlimab (anti-OX40), which have the potential to significantly affect treatment approaches based on promising early trial results.

Panelists discuss how atopic dermatitis severity classification relies on multiple assessment tools including EASI, SCORAD, POEM, and BSA measurements. Special attention is given to sensitive areas (hands, feet, genitals) as they significantly impact quality of life. Disease extent, intensity of symptoms, and functional impairment guide categorization into mild, moderate, or severe cases.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.